“Our SNPsig assays are the same high level of accuracy as our PCR SARS-CoV-2 portfolio,” Mullis said. More variants will be added as they are identified.
“primary challenge for COVID-19 diagnostics companies is ensuring their products continue to accurately test for the virus, regardless of the variant, and to innovate at the challenging pace required to remain clinically relevant"
Sales - £28m > £30m (Yourgene £18>£20m)
Cash - 🤔
COVID prods on sale - 3🤔
Market Cap - £761m
There's a margin of error to account for BBI accounts which aren't public, awaiting GeneDrive which reports 31/03, Avacta account were published 23/01 last yr.
Say £5m tops. Small fry when you consider imbalance of collective market capitalisations.